Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-05-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
湖北得伟君尚律师事务所关于健民药业集团股份有限公司差异化分红事项的专项法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's differentiated dividend distribution matter. It references specific laws, regulations, and company resolutions related to profit distribution and share repurchase. The document is a specialized legal opinion rather than a financial report, earnings release, or regulatory announcement. It does not contain financial statements or management discussion but provides legal assurance on the dividend distribution process. The document length is 3303 characters, which is relatively short and focused on legal opinion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-05-16 Chinese
湖北得伟君尚律师事务所关于健民药业集团股份有限公司2022年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of a company's 2022 first extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting process and the validity of the resolutions passed. The document is short (2022 characters) and focuses on the legal opinion about the shareholder meeting rather than the meeting materials or voting results themselves. It is not a full Annual Report, Audit Report, or Management Report. It is also not a Proxy Solicitation or Voting Results announcement. Given the nature of the document as a legal opinion letter on the shareholder meeting, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2022-05-06 Chinese
健民集团2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2022 first extraordinary general meeting (临时股东大会) of the company. It includes details about the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting summary. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1591 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is DVA with high confidence.
2022-05-06 Chinese
健民集团2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is a detailed set of materials for a 2022 first extraordinary general meeting (临时股东大会) of 健民药业集团股份有限公司. It includes the meeting agenda, voting procedures, detailed proposals regarding the company's subsidiaries applying for bank credit facilities and guarantees, financial data of the subsidiaries, board and independent directors' opinions, and the request for shareholder approval. The content is focused on the meeting materials and agenda for the shareholders to review and vote on, rather than the announcement of voting results or a summary. The document length is over 7,000 characters, indicating it is a full meeting material document rather than a brief announcement. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. It is not an announcement of voting results (DVA), nor a regulatory filing or report publication announcement. Therefore, the classification is AGM-R with high confidence.
2022-04-26 Chinese
健民集团关于投资者交流情况的公告
Call Transcript Classification · 95% confidence The document is a detailed announcement of an investor conference call held on April 18, 2022, discussing the company's Q1 2022 performance, product sales, operational impacts of the pandemic, and future outlook. It includes Q&A with management and references the company's Q1 2022 report disclosed on April 16, 2022. The content is a transcript or summary of the investor call rather than a brief earnings highlight or a formal earnings release. It contains substantive discussion of financial results and business trends, consistent with a Call Transcript (CT). The document length (3586 characters) is sufficient for a detailed transcript but not a full annual or interim report. It is not a simple announcement or regulatory filing, nor is it a presentation or management report. Therefore, the best classification is Call Transcript (CT).
2022-04-18 Chinese
健民集团被担保人基本情况及最近一期财务报表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including balance sheet items, asset and liability figures, and profit and loss data for specific periods (e.g., 2021 year-end audited and 2022 Q1 unaudited). It includes comprehensive financial statements and analysis for a subsidiary company. The length is substantial (15,000 characters), and the content is actual financial data rather than an announcement or certification. There is no indication that this is a full annual report (10-K) for the parent company, but it is a detailed financial report for a period shorter than a full fiscal year (quarterly data is included). Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-04-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.